New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;FB;PMFG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
July 27, 2015
16:00 EDTFBOptions Update; July 27, 2015
Subscribe for More Information
11:57 EDTFBStocks with call strike movement; FB GILD
Subscribe for More Information
09:14 EDTFBFacebook price target raised to $110 from $94 at Cowen
Cowen analyst John Blackledge raised his price target for Facebook (FB) to $110 ahead of the social media giant's Q2 results on July 29. Investor sentiment has grown more positive recently given Facebook's "explosive" video growth and the opening of the Instagram platform to advertisers, Blackledge tells investors in a research note previewing the Q2 results this week for Internet names. He keeps an Outperform rating on the stock. Blackledge also keeps Outperform ratings on LinkedIn (LNKD) and IAC (IACI) as well as a Market Perform rating on Twitter (TWTR). Those three companies are also reporting Q2 results this week.
09:11 EDTFBFacebook price target raised to $125 from $100 at SunTrust
Subscribe for More Information
08:23 EDTFBFacebook July weekly volatility elevated into Q2 and outlook
Facebook August weekly call option implied volatility is at 87, August is at 50, September is at 41; compared to its 52-week range of 19 to 48, suggesting large near term price movement into the expected release of Q2 results on July 29.
08:20 EDTFBFacebook expectations high into results, says BofA/Merrill
Subscribe for More Information
07:01 EDTBMYBristol-Myers, AbbVie say EMA validates for review Empliciti MAA
Bristol-Myers Squibb Company (BMY) and AbbVie (ABBV) announced the European Medicines Agency validated for review the Marketing Authorization Application for Empliciti, an investigational Signaling Lymphocyte Activation Molecule-directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in adult patients who have received one or more prior therapies. The application was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use. Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities. Bristol-Myers Squibb has proposed the name Empliciti which, if approved by health authorities, will serve as the trade name for elotuzumab. The MAA is primarily supported by data from two randomized clinical trials, each combining Empliciti with a different standard of care regimen for multiple myeloma. ELOQUENT-2, a Phase 3, randomized, open-label study, evaluated Empliciti in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone. The results of this trial were published in The New England Journal of Medicine on June 2. Additionally, a Phase 2, randomized, open-label study evaluated Empliciti with bortezomib and dexamethasone versus bortezomib and dexamethasone alone. These Phase 2 results were presented in an oral session at the 20th Congress of the European Hematology Association. Empliciti previously obtained orphan drug designation in the European Union. An orphan medicinal product must be intended for the treatment, prevention or diagnosis of a disease that is life threatening and chronically debilitating; the prevalence in the EU must not be more than five in 10,000. The medicine must be of significant benefit to those affected by the condition. If maintained, orphan drug designation allows sponsors to access a number of incentives including protocol assistance and receive market exclusivity for a ten-year period following approval.
06:23 EDTFBInstagram's mobile ad revenues to reach $2.81B in 2017, eMarketer says
Subscribe for More Information
05:53 EDTFBBrean calls LinkedIn valuation 'problematic' ahead of Q2 results
Subscribe for More Information
July 24, 2015
15:06 EDTFBEarnings Watch: TV networks report as streaming services gain ground
CBS (CBS), Time Warner (TWX), Viacom (VIA, VIAB), and 21st Century Fox (FOX, FOXA) are among TV network companies expected to report quarterly results over the next several weeks, with Comcast (CMCSA, CMCSK) already having reported before the open on July 23. EXPECTATIONS: Time Warner is expected to report EPS of $1.03 on revenue of $6.9B, CBS is expected to report EPS of 73c on revenue of $3.22B, Viacom is expected to report EPS of $1.47 on revenue of $3.22B, and 21st Century Fox is expected to report EPS of 37c on revenue of $6.48B. LAST QUARTER: CBS, Time Warner, and Fox all reported stronger than expected Q1 results, while Viacom reported higher than expected Q2 EPS but missed on revenue. THIS WEEK'S EARNINGS: On the morning of July 23, Comcast reported Q2 EPS of 84c in line with estimates, and revenue of $18.7B versus expectations for $18.14B. Cable customer relationships for the quarter were up 31,000 to 27.3M, driven by increases in double and triple product relationships. During a subsequent conference call, the company noted that TV viewership continues to be under pressure. NEWS: At Re/code's Code Conference on May 27, CBS CEO Leslie Moonves remarked that his network will "probably" sign up for Apple's (AAPL) rumored TV service, and on June 3, CBS announced that its Showtime network will be offered over the internet as a stand-alone streaming service launching in early July for a monthly price of $10.99, with Apple as its first partner. On July 1, Variety quoted sources as saying Viacom was attempting to entice advertisers by offering to construct social-media and digital extensions of traditional TV ad campaigns as the company seeks to move away from Nielsen-based advertising sales. On July 8, the Wall Street Journal reported that Viacom's Paramount Pictures reached an agreement with AMC (AMC) to accelerate the home release of movies, noting that the company hoped to implement the quickened schedule for all new releases beginning later in the year. On July 17, Re/code reported that Viacom held talks to acquire e-commerce and media company Thrillist Media, according to sources. On June 17, 21st Century Fox named James Murdoch as CEO, with founder and former chairman and CEO Rupert Murdoch appointed executive co-chairman alongside Lachlan Murdoch. The Telegraph reported on June 20 that Fox rejected offers for its stake in Sky (SKYAY) from Vodafone (VOD) and Vivendi (VIVHY), potentially signalling an interest in outright purchasing the rest of Sky, according to the report. More recently, the European Commission announced on July 23 that it delivered a statement of objections to Sky and various film studios owned by Comcast, Viacom, Fox, Time Warner, Disney (DIS), and Sony (SNE), discussing anti-trust concerns due to limitations on country-by-country availability of pay-TV services. STREET RESEARCH: On May 12, Pacific Crest said it believes Apple will launch its TV service before the end of the year, saying the move should benefit TV networks as well as Apple itself. On June 24, Brean Capital said Facebook's (FB) agreement with Time Warner to host premier episodes of certain upcoming shows was "a trend worth following," and possibly indicative of Facebook hosting additional TV content in the future. Also on June 24, FBR Capital contended that Netflix (NFLX) was on pace to have a larger 24-hour audience than all traditional broadcast networks, where ratings are seeing declines on average, according to the research firm. Those comments were followed by a July 10 note on Netflix from Morgan Stanley, saying the subscription streaming service was seeing higher time spent per day than any single broadcast network. Moving away from the Netflix factor, on July 10, JPMorgan said CBS shares looked "very attractive" following a recent selloff, though the company saw a downgrade on July 20 from Pivotal, which cited higher costs of capital among other factors. Finally, Citi upgraded Viacom on July 16 to Neutral, citing recent underperformance in the company's shares heading into earnings season.
14:08 EDTBMYBristol-Myers confirms FDA approval of hepatitis drug Daklinza
Subscribe for More Information
14:04 EDTFBOn The Fly: Weekly technical notes on 'FANG' and divergences
Subscribe for More Information
13:52 EDTFBFacebook July weekly volatility increasing into Q2 and outlook
Subscribe for More Information
13:49 EDTBMYFDA approves new treatment for chronic hepatitis C genotype 3
Subscribe for More Information
11:02 EDTBMYBristol-Myers selects Jones Lang LaSalle for facility management
Subscribe for More Information
10:15 EDTFBFacebook wins litigation against investors over IPO, Reuters reports
Subscribe for More Information
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
06:57 EDTFBFacebook July weekly volatility increasing into Q2 and outlook
Subscribe for More Information
July 23, 2015
18:21 EDTBMYOn The Fly: Top stock stories for Thursday
Stocks began the session mixed on the heels of weak earnings reports from both Caterpillar (CAT) and 3M (MMM). The Nasdaq managed to spend most of the day in positive territory but joined the other averages in negative territory by mid-afternoon. Selling picked up momentum towards late afternoon, and by day’s end each of the averages were lower by more than 0.4%, with the Dow losing nearly 0.7%. ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 255,000 in the week ended July 18, below the 278,000 first-time claims that were expected. The Leading Economic Indicators advanced 0.6% in June, exceeding expectations for a 0.3% increase. In Asia, the Shanghai Composite index advanced for a sixth straight session, adding another 2.4%. In Europe, the Greek Parliament voted to accept creditor terms for a new bailout, though a decision on when to reopen Greek financial markets was deferred to next week. COMPANY NEWS: Shares of General Motors (GM) finished the session up 3.96% to $31.50 after reporting earnings per share above analyst expectations. Other notable names rising following earnings reports include SanDisk (SNDK), Under Armour (UA), Southwest (LUV)... Caterpillar, meanwhile, dropped $2.86, or 3.59%, to $76.90 after cutting its yearly guidance during this morning's earnings report, with the company noting a "relatively stagnant" global economy. Also lower following earnings were Comcast (CMCSA, CMCSK), Bristol-Myers Squibb (BMY), Dunkin Brands (DNKN), and Boston Scientific (BSX). MAJOR MOVERS: Among the notable gainers was Cigna (CI), which rose $3.29, or 2.18%, to $154.36 after the Wall Street Journal reported last night that Anthem (ANTM) is nearing a deal to acquire the company for roughly $187, representing a total transaction value of over $48B. Adding to that report, CNBC's David Faber said on Thursday morning that Anthem will announce an agreement Friday to purchase Cigna for $188 per share, at a 45% equity, 55% cash split. Also higher were shares of numerous IT security companies, with FireEye (FEYE) advancing 4.53% and Palo Alto Networks (PANW) adding 2.33% after earnings reports from security firms Fortinet (FTNT) and F5 Networks (FFIV) beat on both top and bottom lines. Fortinet and F5, meanwhile, finished Thursday's session up 10.71% and 7.75% to $46.83 and $127.68, respectively. Among the noteworthy losers following earnings was McDonald's (MCD), which edged down 0.52% to $97.10 after noting that Q2 global comparable sales fell 0.7% for the quarter, including a 2% decline in U.S. same-store sales. Also lower was Hertz (HTZ), which declined 8.53% to $16.45 following a downgrade to Underweight at Morgan Stanley, with the research firm citing increased competition from Uber and similar mobility services. INDEXES: The Dow fell 119.12, or 0.67%, to 17,731.92, the Nasdaq lost 25.36, or 0.49%, to 5,146.41, and the S&P 500 declined 12.00, or 0.57%, to 2,102.15.
13:53 EDTFB“Fab Five” option implied volatility
Subscribe for More Information
09:38 EDTFBActive equity options trading on open
Subscribe for More Information
07:34 EDTBMYBristol-Myers raises FY15 adjusted EPS view to $1.70-$1.80 from $1.60-$1.70
Subscribe for More Information
07:31 EDTBMYBristol-Myers reports Q2 EPS 53c, consensus 36c
Subscribe for More Information
06:38 EDTFBFacebook July weekly volatility increasing into Q2 and outlook
Facebook 7/31/15 weekly call option implied volatility is at 60, August is at 40, September is at 34; compared to its 52-week range of 19 to 48, suggesting large near term price movement into the expected release of Q2 results on July 29.
06:38 EDTBMYBristol-Myers' two Opdivo applications validated by European Medicines Agency
Subscribe for More Information
July 22, 2015
23:09 EDTFBFormer MTV executive joins YouTube as VP of originals, Variety says
Subscribe for More Information
15:26 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
15:02 EDTFBOptions Update; July 22, 2015
Subscribe for More Information
09:46 EDTFBFacebook Q2 revenues tracking slight above consensus, says ITG Research
ITG Research's data analysis indicates Facebook's Q2 North American revenue is tracking to $1.9B, up from a previous estimate of $1.86B, versus consensus of $1.84B due to increased spending per advertiser. Firm estimates total Q2 revenues are tracking to $4.05B versus consensus of $3.98B.
09:38 EDTFBActive equity options trading on open:
Subscribe for More Information
July 21, 2015
16:01 EDTFBOptions Update; July 21, 2015
iPath S&P 500 VIX Short-Term Futures down 13c to 16.20. Option volume leaders: AAPL BAC FB BAC MSFT NFLX AMD IBM CHK
14:03 EDTBMYBristol-Myers: Data from Phase IIa study support further evaluation of BMS955176
Bristol-Myers Squibb announced additional Phase IIa proof-of-concept data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1. The study findings, which are being presented in a late-breaking oral presentation at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, confirmed the antiretroviral activity of BMS-955176 when administered with atazanavir and support further development of the second-generation HIV-1 maturation inhibitor. BMS-955176 is designed to inhibit one of the last steps of the HIV-1 viral lifecycle, resulting in the release of immature non-infectious HIV-1 particles. As part of a multi-part proof-of-concept study, a two-drug combination of BMS-955176 plus atazanavir had a maximum median change in HIV-1 RNA of -2.23 log10 c/mL from baseline through study discharge. The standard of care control of atazanavir 300 mg and ritonavir 100 mg plus tenofovir disoproxyl fumarate 300 mg plus emtricitabine 200 mg in a fixed dose combination had a maximum median change in HIV-1 RNA of -2.39 log10 c/mL from baseline through study discharge. In addition, a lower dose of BMS-955176 plus atazanavir and ritonavir had a similar maximum median change in HIV-1 RNA of -2.20 log10 c/mL. Length of therapy for all treatment groups was 28 days. Study endpoints included change in HIV-1 RNA from baseline to Day 28 and from baseline to the end of the study and safety. Data from Part A and Part B of the Phase IIa proof-of-concept study support the further evaluation of BMS-955176 in novel treatment regimens such as nucleos(t)ide- and booster-sparing regimens to address key unmet needs for HIV-1 treatment-experienced patients. Two Phase IIb studies have started in 2015: a traditional dose-finding study in treatment-naive patients and a second Phase IIb study to evaluate a nucleos(t)ide- and booster-sparing regimen in treatment-experienced patients.
09:35 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL FB IBM TSLA BAC PVA NFLX
09:02 EDTBMYBristol-Myers Squibb receives FDA breakthrough designation for HIV-1 inhibitor
Bristol-Myers Squibb announced that the FDA has granted Breakthrough Therapy Designation to the investigational compound BMS-663068 when used in combination with other antiretroviral, or ARV, agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients. BMS-663068 is an oral prodrug of the molecule BMS-626529 and first-in-class HIV-1 attachment inhibitor. The attachment inhibitor is designed to work differently than entry inhibitors, a current class of drugs that targets co-receptors’ activity or fusion after HIV attaches to the CD4+ host cell. BMS-663068 is thought to work at an earlier point in the replication process to prevent the virus’ initial interaction with immune cells entirely, and thus blocks its entry into the cell.
08:05 EDTFBFacebook added to US 1 List at BofA/Merrill
Subscribe for More Information
07:45 EDTFBSell PayPal amid mounting payments competition, Piper says
Shares of PayPal (PYPL) advanced over 5% yesterday in the stock's first day of trading following a split from eBay (EBAY), with the majority of research firms issuing optimistic notes on its prospects. This morning, however, analyst Gene Munster of Piper Jaffray recommends selling the share as competition grows in the digital payments space. BEARS: Munster started shares of PayPal with an Underweight rating, the firm's equivalent of a "Sell," saying increased competition could pressure the stock's multiple over the next 6-24 months. Google's (GOOG) Android Pay and Apple's (AAPL) Apple Pay will give consumers a "real alternative to PayPal" for the first time, Munster tells investors in his research note. In addition, interest in payments from Amazon.com (AMZN) and Facebook (FB) bring potential for more digital wallet offerings, the analyst notes. Munster set a $30 price target for PayPal. Of note, Evercore ISI also started coverage of PayPal shares yesterday with a Sell rating. BULLS: Wells Fargo initiated coverage of PayPal yesterday with an Outperform rating, saying the company's unique assets will enable it to maintain its leadership role in digital payments and benefit from the growth of e-commerce. Also upbeat was Robert W. Baird analyst Colin Sebastian, who contends that PayPal has the top pure play online payment system and is continuing to grow its share of the Internet payment market. PayPal should be able to innovate more effectively after its spin-off, added the analyst, who set a $45 price target on the shares. PRICE ACTION: Shares of PayPal are pointing toward further gains in their second day of standalone trading, with the stock up about 2.7% to $41.55 in pre-market trading.
06:58 EDTFBFacebook added to US 1 List at BofA/Merrill
Subscribe for More Information
06:19 EDTFBSilicon Valley giants side with Samsung in battle with Apple, InsideSources says
Subscribe for More Information
05:34 EDTFBPayPal initiated with an Underweight at Piper Jaffray
Piper Jaffray analyst Gene Munster started shares of PayPal (PYPL) with an Underweight rating saying increased competition could pressure the stock's multiple over the next 6-24 months. Underweight is Piper's equivalent of a sell rating. Google's (GOOG) Android Pay and Apple's (AAPL) Apple Pay will give consumers a "real alternative to PayPal" for the first time, Munster tells investors in a research note. In addition, interest in payments from Amazon.com (AMZN) and Facebook (FB) bring potential for more digital wallet offerings, the analyst notes. Munster set a $30 price target for PayPal, which began trading yesterday following a spinoff from parent company eBay (EBAY). Shares of the online payment system closed Monday up $2.08 to $40.47.
July 20, 2015
16:01 EDTFBOptions Update; July 20, 2015
Subscribe for More Information
12:40 EDTFBEarnings Watch: IBM up 4% since last quarterly report
Subscribe for More Information
12:35 EDTFBFacebook July weekly volatility increasing into Q2 and outlook
Facebook 7/31/15 weekly call option implied volatility is at 53, August is at 38, September is at 33; compared to its 52-week range of 19 to 48, suggesting large near term price movement into the expected release of Q2 results on July 29.
12:09 EDTBMYBristol-Myers says Nivolumab BMS approved in EU for SQ NSCLC
Subscribe for More Information
12:08 EDTBMYOn The Fly: Top stock stories at midday
Stocks on Wall Street were slightly higher at midday in the first trading day of a week that will be light on domestic economic data but heavy on earnings reports. Investors will be receiving profit reports from about 25% of the companies on the S&P 500 this week, making this the highest volume earnings week of this season. ECONOMIC EVENTS: In the U.S., no major data was released. In Europe, Greece reopened its banks three weeks after closing as the country worked out another bailout agreement. The country announced it has started the process of paying off its creditors, including the European Central Bank and the International Monetary Fund, with a bridge loan it just received. COMPANY NEWS: Lockheed Martin (LMT) agreed to buy the Sikorsky Aircraft business from United Technologies (UTX) for $9B, noting the price is "effectively reduced" to $7.1B after taking into account tax benefits resulting from the transaction. Shares of Lockheed, which also reported better than expected second quarter results and increased its fiscal year guidance, gained nearly 2% after the Sikorsky announcement and saying it will conduct a strategic review of its government IT infrastructure services business and technical services business... Shares of Morgan Stanley (MS) shares were little changed near noon after the bank reported earnings and revenue, excluding certain adjustments, that topped analysts' consensus forecasts... SunEdison (SUNE) announced a deal to acquire Vivint Solar (VSLR) for approximately $2.2B, payable in a combination of cash, shares of SunEdison common stock and SunEdison convertible notes. In connection with the proposed acquisition of Vivint Solar, SunEdison has entered into a definitive purchase agreement with a subsidiary of TerraForm Power (TERP) which, concurrently with the completion of SunEdison's acquisition of Vivint, will acquire Vivint Solar's rooftop solar portfolio, consisting of 523 MW expected to be installed by year-end 2015, for $922M in cash. Shares of Vivint rose 44% following the announcement, while SunEdison's stock gained 4% and TerraForm dropped 3%. Fellow residential solar installer SolarCity (SCTY), which is backed by Tesla's (TSLA) Elon Musk, rose 7% following the deal in the space. MAJOR MOVERS: Among the notable gainers was Exelixis (EXEL), which rallied 43% after the company reported that a study of cabozantinib in metastatic renal cell carcinoma met its primary endpoint of significant improvement in progression-free survival. The shares were indicated to rise even more in early pre-market trading, but lost some of their gains after Bristol-Myers (BMY) announced that its Opdivo study was stopped early after showing superior overall survival in a Phase 3 study of previously treated patients with advanced or metastatic renal cell carcinoma. Bristol-Myers rose a bit less than 1% to trade near $70 per share after its own announcement. Also higher was PayPal (PYPL), which gained more than 5.5% in its first day of trading after being spun out of eBay (EBAY). Meanwhile, eBay shares rose over 2%. Cal-Maine Foods (CALM) dropped 8% after posting lower than expected sales and profits in its fourth quarter and warning that while it should have an adequate supply of its primary feed ingredients, the company expects that prices will be "volatile" in the year ahead. Also lower were shares of several gold miners, including Barrick Gold (ABX) and Newmont Mining (NEM), which each fell about 11%, as gold prices declined about 2% near midday. INDEXES: Near midday, the Dow was up 31.66, or 0.18%, to 18,118.11, the Nasdaq was up 9.81, or 0.19%, to 5,219.96, and the S&P 500 was up 2.82, or 0.13%, to 2,129.46.
11:29 EDTFBFacebook breakout accelerates, levels to watch
Subscribe for More Information
08:56 EDTFBFacebook price target raised to $117 at BTIG on video opportunity
BTIG analyst Richard Greenfield believes Facebook can exceed consensus estimates, citing higher confidence in the company's video advertising opportunity. Greenfield, who raised his revenue estimates for Facebook in this year and next, also points out Instagram's monetization opportunity and the platform potential of WhatsApp and Messenger. The analyst raised his price target on Facebook to $117 from a "stale" target of $80 that had been set in July of last year and reiterates a Buy rating on the social network's stock, which closed at $94.97 on Friday.
08:28 EDTBMYExelixis off highs, but still up 34% after Bristol-Myers data
Subscribe for More Information
08:05 EDTBMYBristol-Myers says Phase III study evaluating Opdivo stopped early
Subscribe for More Information
07:33 EDTBMYInternational AIDS Society to hold a conference
Subscribe for More Information
July 17, 2015
16:01 EDTFBOptions Update; July 17, 2015
Subscribe for More Information
12:38 EDTFBOn The Fly: Top stock stories at midday
Subscribe for More Information
11:34 EDTFBGoogle price targets hiked after 'thesis-changing' quarter
Subscribe for More Information
10:09 EDTFBInstagram picks Eva Chen as head of fashion partnerships, Mashable reports
Subscribe for More Information
10:01 EDTFBFacebook July volatility increasing into Q2 and outlook
Facebook 7/31/15 weekly call option implied volatility is at 41, August is at 31, September is at 28; compared to its 52-week range of 19 to 48, suggesting large near term price movement into the expected release of Q2 results on July 29.
09:35 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL NFLX TSLA GOOG FB GOOGL SLB
09:35 EDTFBFacebook hits fresh life, levels to watch
Subscribe for More Information
06:46 EDTFBJPMorgan puts $800 target on Google after 'thesis-changing' Q2
Subscribe for More Information
06:25 EDTFBGoogle price target raised to $780 from $670 at Deutsche Bank
Subscribe for More Information
05:49 EDTFBGoogle price target raised to $723 from $631 at Piper Jaffray
Piper Jaffray analyst Gene Munster raised his price target for Google shares to $723 saying the search giant's Q2 earnings report and corresponding commentary leave him more confident in the stock over the next two quarters. In addition to talking about a focus on costs, Google noted that mobile cost-per-clicks were up and continued to close the gap on desktop and also highlighted accelerating YouTube usage despite recent media coverage on Facebook (FB) Video, Munster tells investors this morning in a research note. He keeps an Overweight rating on Google. The stock is $62.95 to $642.80 in pre-market trading following last night's earnings report.
July 16, 2015
16:00 EDTFBOptions Update; July 16, 2015
iPath S&P 500 VIX Short-Term Futures down 1.17 to 16.52 Option volume leaders: NFLX AAPL BAC FB F INTC C EBAY AMZN GM JPM MU PFE BABA JD X
13:36 EDTFBFacebook's Instagram says some users having trouble logging in
Instagram said in a tweet, "We're currently experiencing an issue that may have caused some users to have trouble logging in. We’re working hard to fix it." Reference Link
13:02 EDTFBEarnings Watch: Analysts positive on Google long-term outlook ahead of Q2 report
Subscribe for More Information
11:49 EDTFBFacebook's Oculus confirms acquisition of Pebbles Interfaces
Oculus announced on its blog that it has entered into an agreement to acquire Pebbles Interfaces, "one of the leading teams in depth sensing technology and computer vision. Based in Israel, Pebbles Interfaces has spent the past five years developing technology that uses custom optics, sensor systems and algorithms to detect and track hand movement. Over time, technology breakthroughs in sensors will unlock new human interaction methods in VR and revolutionize the way people communicate in virtual worlds. Pebbles Interfaces will be joining the hardware engineering and computer vision teams at Oculus to help advance virtual reality, tracking, and human-computer interactions." Reference Link
09:35 EDTFBActive equity options trading on open
Subscribe for More Information
09:22 EDTBMYBristol-Myers says EU approves Evotaz for treatment of HIV-1 infection in adults
Subscribe for More Information
09:01 EDTBMYuniQure has reached compelling entry point, says Roth Capital
Subscribe for More Information
08:53 EDTFBFacebook to buy Pebbles for about $60M, WSJ reports
Subscribe for More Information
08:14 EDTFBFacebook faces foreign exchange headwinds in Q2, says Brean Capital
Subscribe for More Information
July 15, 2015
16:00 EDTFBOptions Update; July 15, 2015
Subscribe for More Information
09:32 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL FB BAC RCPT MU YUM NFLX CELG
09:18 EDTFBAdobe's Flash disabled by Google due to security worries, WSJ says
Just days after Facebook's (FB) top security executive called on Adobe (ADBE) to discontinue its Flash animation player, Google’s (GOOG) Chrome and Mozilla’s Firefox browsers blocked old versions of the software on Tuesday after reports that hackers were using a security flaw to infiltrate computers, reported The Wall Street Journal's "Digits" blog. Firefox and Chrome will allow Flash to run again if it is updated with the patch Adobe released Tuesday morning, the report noted. Reference Link
08:33 EDTFBFacebook target raised to $110 at Morgan Stanley on mobile ad strength
Morgan Stanley raised 2015 and 2016 revenue estimates for Facebook and increased its price target on the shares to $110 due to scale and improving products. The firm's mobile ad checks indicate Facebook is still the mobile industry leader, has low pricing and high ad ROI, and continues to pull in a larger share of ad budgets and ad dollars per MAU. Morgan Stanley has an Overweight rating on shares of the social network owner, which closed yesterday at $89.68.
08:32 EDTBMYBristol-Myers Squibb, MUSC announce translational research collaboration
The Medical University of South Carolina, or MUSC, and Bristol-Myers Squibb (BMY) announced that they have entered into a translational research collaboration focused on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis. The agreement includes studies designed to improve the mechanistic understanding of fibrosis, explore patient segmentation based on disease characteristics and/or biomarker approaches and predictors of disease progression.
08:27 EDTFBAdobe says Google display ad strategy underperforms Facebook in Q2
In its "Digital Advertising & Social Intelligence Report" for Q2, Adobe (ADBE) wrote that Facebook's (FB) display ad changes doubled its click-through-rates, or CTRs, year-over-year in the quarter, while Google's (GOOG) display targeting changes reduced its number of ads seen by 22% compared to the prior year and its CTRs were up "only" 24% compared to the same period of last year. The report also contends that the "Mobilegeddon" fears regarding Google's changes to favor mobile friendly sites came true, noting that sites with low mobile engagement saw up to a 10% decrease in organic traffic after the changes were made by the search giant. Reference Link
July 14, 2015
16:01 EDTFBOptions Update; July 14, 2015
iPath S&P 500 VIX Short-Term Futures down 15c to 17.76 Option volume leaders: AAPL FB BAC T AMZN BABA INTC JPM LVS AAL CHK MSFT NFLX TSLA TWTR MPC
09:35 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL FB BAC T AMZN BABA INTC JPM LVS AAL CHK MSFT
06:46 EDTFBFacebook Messenger to add 'Moneypenny' feature, The Information reports
Subscribe for More Information
06:14 EDTFBFacebook's Instagram has 14M monthly active users in U.K., Business Insider says
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use